Dark

Check out our API

CRXTW
CLARUS THERAPUTCS HLDG WT
stock OTC

Inactive

Sep 6, 2022

0.0101USD-26.277%(-0.0036)136,141

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 18, 2022

09:05AM EST Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience GlobeNewswire Inc

Dec 7, 2021

04:05PM EST Proceeds to support the ongoing commercialization of JATENZO (testosterone undecanoate) GlobeNewswire Inc

Nov 30, 2021

09:05AM EST JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions GlobeNewswire Inc

Nov 18, 2021

04:05PM EST Third quarter 2021 revenue increased 93% year-over-year to $4.3 million GlobeNewswire Inc

Nov 17, 2021

04:05PM EST Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 18, 2021, after the market closes. GlobeNewswire Inc

Oct 26, 2021

09:05AM EDT JATENZO (testosterone undecanoate) is the first and only FDA-approved oral softgel for testosterone replacement therapy (TRT) in adult males who have deficient testosterone due to certain medical conditions GlobeNewswire Inc

Sep 22, 2021

09:05AM EDT Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present at the 2021 Cantor Virtual Global Healthcare Conference, Monday, September 27, 2021, 10:40 a.m. ET. GlobeNewswire Inc

Sep 16, 2021

09:05AM EDT Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases GlobeNewswire Inc

Sep 15, 2021

09:05AM EDT Clarus Therapeutics Holdings, Inc. (Nasdaq:CRXT), a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, Monday, September 20, 2021, 2:05 p.m. ET. GlobeNewswire Inc

Share